Discover
PTGX
Protagonist Therapeutics, Inc.
125.17
2 x 90.28
2 x 157.31
bid
ask
+
2.59
2.11%
2 @ 04:00 PM
124.67 -0.50 (0.40%)
| Ytd | 43.31% | |
| 1y | 146.93% |
122.50
day range
126.04
49.38
52 week range
126.59
| Open | 122.96 | Prev Close | 122.58 | Low | 122.50 | High | 126.04 | Mkt Cap | 8.05B |
| Vol | 490.15K | Avg Vol | 691.19K | EPS | -1.81 | P/E | N/A | Forward P/E | -179.04 |
| Beta | 1.83 | Short Ratio | 13.55 | Inst. Own | 125.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 105.19 | 200-d Avg | 90.00 | 1yr Est | 118.69 |
PTGX News
accessnewswire.com
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today rep
benzinga.com
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major
benzinga.com
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its
benzinga.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d
benzinga.com
Protagonist Therapeutics To Present Four Abstracts On Rusfertide In Polycythemia Vera At 2026 Europe
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that